IP Library Granted Patent US 9,593,306
Granted Patent B2
US 9,593,306 · App. 13/434,409 · Granted Mar 14, 2017

Differentiation of pluripotent stem cells

Inventors: Janet Davis (Skillman, NJ); Jiajian Liu (Skillman, NJ); Christine Parmenter (Skillman, NJ); Pascal Ghislain André Bonnet (Beerse, BE)
Assignee: Janssen Biotech, Inc.
C12N5/0606C12N5/0678
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,593,306
App. No.
13/434,409
Granted
Mar 14, 2017
Kind
B2
Abstract

The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.

Claims (13)

1. A method to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage, comprising treating the pluripotent stem cells with a medium lacking activin A, and containing GDF-8 and a cyclic analine-pyridinotriazine comprising 5-Chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜]tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one, for a period of time sufficient for the pluripotent stem cells to differentiate into cells expressing markers characteristic of the definitive endoderm lineage.

2. The method of claim 1 , wherein the method increases the percentage of cells expressing CXCR4.

3. The method of claim 1 , wherein the medium further comprises EGF, FGF or EGF and FGF and wherein the method enhances expression of SOX17.

4. The method of claim 1 , wherein the medium is further lacking Wnt3a.

5. The method of claim 1 , wherein the medium further comprises at least one factor selected from the group consisting of: PDGF-A, PDGF-B, PDGF-C, PDGF-D, VEGF, muscimol, PD98059, LY294002, U0124, U0126, and sodium butyrate.

6. A method of enhancing the differentiation of pluripotent stem cells into definitive endoderm lineage cells comprising differentiating pluripotent stem cells into definitive endoderm cells by culturing the pluripotent stem cells for about one to about three days with a medium lacking activin A, and containing GDF-8 and 5-Chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜]tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one.

7. The method of claim 6 , wherein the medium further comprises at least one factor selected from the group consisting of: EGF, FGF4, PDGF-A, PDGF-B, PDGF-C, PDGF-D, VEGF, muscimol, PD98059, LY294002, U0124, U0126, and sodium butyrate.

8. The method of claim 6 , wherein the method comprises culturing the pluripotent stem cells with a medium lacking activin A, and containing GDF-8 and 5-Chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜]tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one for about one day.

9. A method of enhancing the yield of definitive endoderm cells in a population comprising definitive endoderm cells comprising: differentiating a population of pluripotent stem cells into the population comprising definitive endoderm cells by culturing the pluripotent stem cells in a medium lacking activin A, and containing GDF-8 and 5-Chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜]tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one.

10. The method of claim 9 , wherein the method comprises culturing in the medium from about one to about three days.

11. The method of claim 9 , wherein the medium further comprises at least one factor selected from the group consisting of: EGF, FGF4, PDGF-A, PDGF-B, PDGF-C, PDGF-D, VEGF, muscimol, PD98059, LY294002, U0124, U0126, and sodium butyrate.

12. The method of claim 1 , wherein said method enhances differentiation into the definitive endoderm lineage when compared to cells treated with a medium comprising activin A.

13. The method of claim 1 , wherein the cells are cultured in the medium for about one to seven days.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2017
From: DAVIS, JANET; LIU, JIAJIAN; PARMENTER, CHRISTINE; BONNET, PASCAL GHISLAIN ANDRE
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 041066/0194 →
CHANGE OF NAME Recorded Jan 24, 2017
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 041470/0865 →
Continuity (5)
Continuation 12494789 · Jun 30, 2009
Provisional Application 61076900 · Jun 30, 2008
Provisional Application 61076908 · Jun 30, 2008
Provisional Application 61076915 · Jun 30, 2008
Related Publication 20120196365A1 · Aug 2, 2012